CHV

Epitel Receives FDA 510(k) Clearance for Two New Technologies: REMI Remote EEG Monitoring System for Ambulatory Use and REMI Vigilenz AI For Event Detection

Retrieved on: 
Mardi, avril 23, 2024
FDA, Health, Medical Devices, Cloud, OSF, Brain, Patient, PCCP, Seizure, Food, Software, MD, Doctor of Philosophy, Neurology, Physician, REMI, Caregiver, Harvard Medical School, Diagnosis, EEG, CHV, Food and Drug Administration, Medical device

REMI Ambulatory and REMI Vigilenz AI For Event Detection will help patients and providers make better-informed treatment decisions,” said Mark Lehmkuhle, PhD, Chief Executive Officer and Co-Founder of Epitel.

Key Points: 
  • REMI Ambulatory and REMI Vigilenz AI For Event Detection will help patients and providers make better-informed treatment decisions,” said Mark Lehmkuhle, PhD, Chief Executive Officer and Co-Founder of Epitel.
  • REMI Vigilenz AI for Event Detection leverages state-of-the-art proprietary machine learning to identify and annotate potential seizure events in REMI EEG records.
  • REMI Vigilenz AI For Event Detection is indicated for the analysis of REMI Remote EEG Monitoring System electroencephalogram (EEG) recordings.
  • REMI Vigilenz AI For Event Detection does not mark REMI EEG records in real time and does not provide any diagnostic conclusion about the patient's condition to the user.

CSE Bulletin: Fundamental Change - Canada House Cannabis Group Inc./MTL Cannabis Corp

Retrieved on: 
Mercredi, août 16, 2023
CSE, CHV, Disclosure, Dan Rush, Patient, Cannabis, Drug, Louiseville

Toronto, Ontario--(Newsfile Corp. - Le 16 août/August 2023) - The common shares of MTL Cannabis Corp. (MTLC) previously listed as Canada House Cannabis Group Inc. (CHV) have been approved for listing on the CSE.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - Le 16 août/August 2023) - The common shares of MTL Cannabis Corp. (MTLC) previously listed as Canada House Cannabis Group Inc. (CHV) have been approved for listing on the CSE.
  • Listing and disclosure documents will be available at www.thecse.com on the trading date.
  • ft. production facility; and Canada House Clinics Inc., with clinics across Canada that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions.
  • Les actions ordinaires de MTL Cannabis Corp. (MTLC) précédemment répertoriées sous le nom de Canada House Cannabis Group Inc. (CHV) ont été approuvées pour être inscrites à la CSE.

Foot Levelers Launches Summer 2023 Custom Orthotic Sandals, Flip-Flops and Golf Orthotics for Proprioception, Alignment and Body Performance.

Retrieved on: 
Mardi, mai 16, 2023
Managed Care, Men, Sports, General Health, Other Retail, Specialty, Consumer, Golf, Fitness & Nutrition, Retail, Women, Footwear, Health, Stroke, CHV, Foot, Proprioception, Woman, Multimedia, Foot Levelers, Athlete, Levellers, Risk, Shoe, Fatigue, Shoemaking, Greenawalt

Men and women benefit from improved proprioception, or the act of sensing motion and position of the body, which is a key element of athletic performance and injury prevention.

Key Points: 
  • Men and women benefit from improved proprioception, or the act of sensing motion and position of the body, which is a key element of athletic performance and injury prevention.
  • The custom design includes magnets that help to increase energy and stamina on the green while concurrently reducing fatigue.
  • As featured in all Foot Levelers custom, flexible orthotics, ParFlex Plus is built with a proprietary 3 Arch Advantage™ which provides support all three arches of the foot, which is the only way to properly address total body wellness from the ground up.
  • Whether you are on the golf course or the boardwalk this summer, Foot Levelers can help you start off on the right foot!”

Joint Early Warning News Release Issued with Respect to the Acquisition of Securities of Canada House Cannabis Group Inc.

Retrieved on: 
Mercredi, août 31, 2022
Security (finance), Related, CSE, National instrument, Cannabis, Time, Sale, Ownership, Share (finance), House, MTL, CHV, News, Transaction, Acquiring bank, SEDAR, Acquisition, Cryptocurrency, Machine tool, Law, Canada House

On August 30, 2022, Canada House announced the closing of the first tranche of its previously announced acquisition (the "Transaction") of all of the issued and outstanding shares of Montral Cannabis Mdical Inc. ("MTL Cannabis").

Key Points: 
  • On August 30, 2022, Canada House announced the closing of the first tranche of its previously announced acquisition (the "Transaction") of all of the issued and outstanding shares of Montral Cannabis Mdical Inc. ("MTL Cannabis").
  • None of the Acquirors owned, controlled or directed any securities of Canada House prior to completion of the first tranche of the Transaction.
  • An early warning report will be filed by the Acquirors under applicable securities laws and will be available on Canada House SEDAR profile at www.sedar.com .
  • A copy of the early warning report may also be obtained by contacting Steven Pearce, Vice-President, Legal, Canada House Cannabis Group, 1773 Bayly Street, Pickering, Ontario, L1W 2Y7, 289-980-3584, [email protected]

OSF Ventures joins early financing for first FDA-cleared wireless seizure detection sensor

Retrieved on: 
Jeudi, mars 10, 2022
Time, Forehead, Adult, Scalp, World Health Organization, Third order, FDA, EEG, Neurodegeneration, Quality of life, OSF HealthCare, Seizure, Wireless, Lists of diseases, Ear, News, Nursing, Critical care, Multimedia, Noise, Hospital, Ambulatory, Prevalence, World, DXCM, Bed, Doctor of Philosophy, Patient, REMI, Sister, Technology, Government budget balance, Population, OSF, Caregiver, Epilepsy, Diagnosis, CHV, View, Partner (business rank), Medical device, Medical imaging

Catalyst Health Ventures (CHV) and Genoa Ventures co-led the over-subscribed early financing along with participation from Dexcom, Inc. (DXCM), Wavemaker 360, and existing investors MedMountain Ventures and Salt Lake City Angels.

Key Points: 
  • Catalyst Health Ventures (CHV) and Genoa Ventures co-led the over-subscribed early financing along with participation from Dexcom, Inc. (DXCM), Wavemaker 360, and existing investors MedMountain Ventures and Salt Lake City Angels.
  • The one-inch square Epitel wireless sensor has a proprietary adhesive that easily sticks discreetly on a patient's scalp, just below the hairline.
  • OSF Ventures will be collaborating with Epitel to further support its value proposition as the company works to commercialize its REMI platform.
  • OSF HealthCare, through OSF Home Care Services, operates an extensive network of home health and hospice services.

Epitel Secures $12.5 Million Series A Financing for Wearable, Wireless EEG Monitoring System

Retrieved on: 
Mercredi, février 16, 2022
Biotechnology, Medical Devices, Hardware, Health, Technology, Colorado EKG Repository, ICU, Patient, Seizure, Epilepsy, Venture, CEO, Â, Neurology, EEG, Brain, REMI, Rafael L. Bras, CHV, Review, Ward, Epilepsy Foundation, Medtech, Geography, Biology, Doctor of Philosophy, Director, FDA, Population, View, Board, Innovation, NIH, Heart, Principal, Multimedia, Diagnosis, OSF, Investment, Independent director, Life, OSF HealthCare, Medical device, Bank, Medical imaging, Dexcom, Transformation/transcription domain-associated protein

Epitel, Inc. , a digital health company developing a wearable, wireless EEG monitoring platform for seizure detection, announced today the closing of a $12.5 million Series A financing for initial pilot commercialization and further development of its proprietary platform.

Key Points: 
  • Epitel, Inc. , a digital health company developing a wearable, wireless EEG monitoring platform for seizure detection, announced today the closing of a $12.5 million Series A financing for initial pilot commercialization and further development of its proprietary platform.
  • View the full release here: https://www.businesswire.com/news/home/20220216005643/en/
    Epitel introduces REMI, a wearable, wireless EEG monitoring platform for seizure detection.
  • Because the Epitel System is wearable and wireless, it can continue to monitor the patient continuously for 48 hours during their hospital journey.
  • Epitel is a digital health company developing a wearable, wireless EEG monitoring platform to provide accessible, affordable, and reliable for seizure detection.